INMB (INmune Bio) E10: $-1.34 (As of Mar. 2026)


INMB INmune Bio Inc INMB
52 GF Score
Price $1.36
GF Value $1.84
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is INmune Bio E10?

INmune Bio INMB -4.59% 52 E10 is $-1.34 as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 52/100 and a GF Value™ of $1.84 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

INmune Bio's adjusted earnings per share data for the fiscal year that ended in Dec. 2025 was $-1.860. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.34 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-24), INmune Bio's current stock price is $ 1.355. INmune Bio's E10 for the fiscal year that ended in Dec. 2025 was $-1.34. INmune Bio's Shiller PE Ratio of today is .


INmune Bio  (NAS:INMB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


INmune Bio E10 Related Terms


INmune Bio E10 Historical Data

* Premium members only.

The historical data trend for INmune Bio's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

INmune Bio E10 Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.34

INmune Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.34 0.00

INMB vs GRDX, VERU, ABVC: E10 Comparison

For the Biotechnology subindustry, INmune Bio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where INmune Bio's Shiller PE Ratio falls into.


INMB
52GF Score
INmune Bio Inc INMB
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

INmune Bio E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, INmune Bio's adjusted earnings per share data for the fiscal year that ended in Dec. 2025 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-1.86/324.0540*324.0540
=-1.860

Current CPI (Dec. 2025) = 324.0540.

INmune Bio Annual Data

per_share_eps CPI Adj_EPS
201612 -0.025 241.432 -0.034
201712 -0.074 246.524 -0.097
201812 -1.109 251.233 -1.430
201912 -0.750 256.974 -0.946
202012 -1.010 260.474 -1.257
202112 -1.880 278.802 -2.185
202212 -1.520 296.797 -1.660
202312 -1.670 306.746 -1.764
202412 -2.110 315.605 -2.166
202512 -1.860 324.054 -1.860

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-1.34 mean?
INmune Bio (INMB) has a E10 of $-1.34 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on INmune Bio and its competitors.
Is INmune Bio's E10 too high?
INmune Bio's current E10 is $-1.34. Overall, INmune Bio has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's E10 compare to GRDX and VERU?
INmune Bio's E10 of $-1.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on INmune Bio and its competitors. INmune Bio's current E10 is $-1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.84, compared to a current price of $1.36 — trading 26.4% below its estimated fair value. The current E10 is $-1.34. INmune Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For INmune Bio (INMB), the current E10 is $-1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.36 is trading 26.4% below its estimated GF Value™ of $1.84. GuruFocus considers INmune Bio to be Modestly Undervalued.

Key valuation signals for INMB:

  • E10: $-1.34
  • GF Value™: $1.84 vs. price of $1.36 (26.4% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score

Get the complete analysis for INMB

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.36
Price
$1.84
GF Value